Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting ...

In the gut mucosa of IgAN patients, expanded IgA+ plasma cells highly express BCMA, supported by APRIL signals, leading to excess pathogenic IgA and kidney injury. Therapeutic depletion of these BCMA+ ...

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. For decades, the "gut-kidney axis" hypothesis has suggested that the ...

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

The campaign features newly published research from Board members living with IgAN, alongside new educational resources ...

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

Add Yahoo as a preferred source to see more of our stories on Google. May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ...

In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years ...

Cutting down on sodium when you have IgAN can help preserve your kidney function. Learn ways to drop salt without forgetting ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...